Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. (6th May 2019)

• Record Type: Journal Article
• Authors: Waters, Valerie J; Kidd, Timothy J; Canton, Rafael; Ekkelenkamp, Miquel B; Johansen, Helle Krogh; LiPuma, John J; Bell, Scott C; Elborn, J Stuart; Flume, Patrick A; VanDevanter, Donald R; Gilligan, Peter
• Is Part Of: Clinical infectious diseases. Volume 69:Number 10(2019)
• Page Start: 1812
• Page End: 1816
• Publication Date: 2019-05-06
• Subjects: cystic fibrosis -- antimicrobial susceptibility; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciz364
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward. Abstract : Current antimicrobial susceptibility testing does not predict clinical response to antimicrobial treatment of chronic lung infections such as in cystic fibrosis. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy.